Features

Features

Decentralised clinical trials and sites: friend or foe?

While the notion of sites disappearing from clinical trials is not a threat anymore, sponsors need to ensure appropriate support to avoid technological burdens.

Urtė Fultinavičiūtė

Features

Managed access programmes: expanding clinical development plans for patients in need

Features

Analysis: Expanded access compliance falters among US drug companies

Features

Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy

Features

Duchenne muscular dystrophy: major trials and events to watch in 2023

Features

FDA guidance agenda: what is CDER cooking for clinical trials?

Features

Pipeline Moves: advancement prospects slump for lupus drug after negative topline data

Features

Quantum medicine: how quantum computers could change drug development

Features

A year of Russia’s war in Ukraine: who is winning the battle on clinical trials?

Urtė Fultinavičiūtė and Irena Maragkou

Features

Pipeline Moves: positive topline results for epilepsy drug, advancement prospects jump

Clinical Trials Arena Team

Features

Delaying type 1 diabetes progression: major trial readouts to watch in 2023

Features

FDA drug dosage optimisation guidelines signal clinical trial reform

Features

Patient recruitment: can pharmacists fill both prescriptions and clinical trials?

Urtė Fultinavičiūtė

Features

Pipeline Moves: advancement prospects jump for cardiovascular gene therapy

Clinical Trials Arena Team

Features

mRNA vaccines: Four major clinical trial readouts to watch in 2023

Features

Mapping endpoints: building gene therapy trials for the future

Features

Predictive analytics in drug development: state of play

Urtė Fultinavičiūtė

Features

Pipeline Moves: Trial completion bumps advancement prospects for AstraZeneca’s oncology drug

Clinical Trials Arena Team

Features

Five gene therapy trial readouts to watch in the first half of 2023

Features

Inclusive drugs: designing clinical trials for the pregnant population

Urtė Fultinavičiūtė

Features

DCTs in 2023: New year’s resolutions for decentralised clinical trials

Urtė Fultinavičiūtė

Features

Pipeline Moves: Amgen terminates Phase III osteogenesis imperfecta trial, approval prospects drop

Clinical Trials Arena Team

Features

Phase 0 trials, master protocols to rule nontraditional trial design in 2023

Features

Basket and umbrella trials: Major events to watch in the first half of 2023

Features

Year in review: Who were the main DCT players in 2022?

Urtė Fultinavičiūtė and Irena Maragkou

Features

Pipeline Moves: AbbVie and Janssen terminate Phase III lymphoma trial, approval prospects plummet

Clinical Trials Arena Team

Features

Inside the hunt for an Alzheimer’s disease vaccine

Features

Digital twins: easing the clinical trial conduct but regulatory oversight is needed

Urtė Fultinavičiūtė

Features

Next on diversity: inclusion of participants with cognitive impairment in clinical trials

Urtė Fultinavičiūtė

Features

Alzheimer’s disease drug development: three major questions for 2023

Features

Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise

Clinical Trials Arena Team

Features

Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023

Features

Is the healthcare industry spearheading the metaverse?

Features

Boon and bane: dodging participant burden in decentralised clinical trials

Urtė Fultinavičiūtė

Features

Pipeline Moves: Novartis resumes Phase II myelofibrosis trial, oncology trial completions

Clinical Trials Arena Team

Features

Running low on comparators: navigating drug shortages in oncology clinical trials

Features

ACT EU state of play: EMA’s headway to transform clinical trials

Urtė Fultinavičiūtė

Features

Pipeline Moves: approval prospects jump for AstraZeneca’s breast cancer drug

Clinical Trials Arena Team